- Home
- ATNF vs CERO Comparison
ATNF vs CERO Comparison
Compare ATNF & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- CERO
- Stock Information
- Founded
- ATNF 2016
- CERO 2017
- Country
- ATNF United States
- CERO United States
- Employees
- ATNF N/A
- CERO N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- ATNF Health Care
- CERO
- Exchange
- ATNF Nasdaq
- CERO Nasdaq
- Market Cap
- ATNF 3.8M
- CERO 3.5M
- IPO Year
- ATNF N/A
- CERO N/A
- Fundamental
- Price
- ATNF $0.83
- CERO $9.93
- Analyst Decision
- ATNF
- CERO Strong Buy
- Analyst Count
- ATNF 0
- CERO 2
- Target Price
- ATNF N/A
- CERO $45.00
- AVG Volume (30 Days)
- ATNF 35.4K
- CERO 3.3M
- Earning Date
- ATNF 08-11-2025
- CERO 08-13-2025
- Dividend Yield
- ATNF N/A
- CERO N/A
- EPS Growth
- ATNF N/A
- CERO N/A
- EPS
- ATNF N/A
- CERO N/A
- Revenue
- ATNF N/A
- CERO N/A
- Revenue This Year
- ATNF N/A
- CERO N/A
- Revenue Next Year
- ATNF N/A
- CERO N/A
- P/E Ratio
- ATNF N/A
- CERO N/A
- Revenue Growth
- ATNF N/A
- CERO N/A
- 52 Week Low
- ATNF $0.66
- CERO $6.71
- 52 Week High
- ATNF $17.75
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ATNF 35.60
- CERO 50.09
- Support Level
- ATNF $0.95
- CERO $8.12
- Resistance Level
- ATNF $1.04
- CERO $13.14
- Average True Range (ATR)
- ATNF 0.08
- CERO 2.83
- MACD
- ATNF -0.01
- CERO 0.39
- Stochastic Oscillator
- ATNF 17.41
- CERO 19.58
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.